A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Adenocarcinoma of LungCarcinoma, Non-Small-Cell Lung
Interventions
DRUG

LP-300

LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.

DRUG

Pemetrexed

Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion.

DRUG

Carboplatin

Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.

Trial Locations (16)

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

22031

RECRUITING

Inova Fairfax Hospital, Fairfax

75235

RECRUITING

UT Southwestern Medical Center, Dallas

90212

RECRUITING

Precision NextGen Oncology and Research Center, Beverly Hills

90720

RECRUITING

Cancer and Blood Specialists Clinic, Los Alamitos

92708

RECRUITING

Los Angeles Cancer Network, Fountain Valley

Unknown

RECRUITING

Hokkaido Cancer Center, Sapporo

RECRUITING

Kanagawa Cancer Center Hospital, Yokohama

RECRUITING

Tohoku University Hospital, Sendai

RECRUITING

Okayama University Hospital, Okayama

RECRUITING

National Cancer Center Hospital, Chuo-ku

RECRUITING

Chi Mei Medical Center, Tainan City

RECRUITING

National Cheng Kung University Hospital, Tainan City

RECRUITING

Taipei Veterans General Hospital, Taipei

RECRUITING

TriService General Hospital-Neihu Main Facility, Taipei

RECRUITING

National Taiwan University Hospital Hsin-Chu Branch, Taoyuan District

Sponsors
All Listed Sponsors
lead

Lantern Pharma Inc.

INDUSTRY

NCT05456256 - A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | Biotech Hunter | Biotech Hunter